Graft rejection after unrelated donor hematopoietic stera cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction

被引:98
作者
Fleischhauer, K
Locatelli, F
Zecca, M
Orofino, MG
Giardini, C
de Stefano, P
Pession, A
Iannone, AM
Carcassi, C
Zino, E
La Nasa, G
机构
[1] IRCCS, Policlin San Matteo, Immunohematol & Transfus Med Serv, HLA Tissue Typing Lab, I-27100 Pavia, Italy
[2] Ist Ricovero & Cura & Carattere Sci, San Raffaele Telethon Inst Gene Therapy, HLA Tissue Typing Lab, Immunohematol & Transfus Med Serv, Milan, Italy
[3] Univ Cagliari, Dept Biomed & Biotechnol Sci, Bone Marrow Transplantat Unit, I-09124 Cagliari, Italy
[4] Osped San Salvatore, Dept Hematol, Bone Marrow Transplantat Unit Muraglia, Pesaro, Italy
[5] Univ Bologna, Osped S Orsola Malpighi, Dept Pediat, Bologna, Italy
[6] Osped Binaghi, Bone Marrow Transplantat Unit, Cagliari, Italy
关键词
D O I
10.1182/blood-2005-08-3374
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The success of allogeneic hematopoietic stem cell transplantation (HSCT) from matched unrelated donors (UDs) for beta-thalassemia may be hampered by the occurrence of graft rejection. Here, we show that the rate of this complication can be reduced by selecting 5-loci HLA-matched donors without nonpermissive mismatches at HLA-DPB1, defined according to an algorithm previously described and based on principles of central T-cell tolerance. Seventy-two consecutive patients and their UDs, prospectively selected for matching at the allelic level for HILA-A, -B, -C, -DRB, and -DQB1 loci, were enrolled in the analysis. These pairs were either DPB1 matched/permissively mismatched (n = 45, control group) or had at least one nonpermissive DPB1 mismatch in the host-versus-graft (HvG; n 17) or in the graft-versus-host (GvH; n 10) direction. In multivariate analysis, the risk of rejection was significantly increased in the group with HvG disparity (FIR = 7.42; 95% CI = 1.29-42.68; P = .02) as compared to the control group. A lower, statistically significant, probability of thalassemia-free survival was found in patients belonging to the HvG group as compared to controls (FIR = 5.15; 95% CI = 1.58-16.82; P = .01). These data suggest that in patients with thalassemia, the incidence of graft failure after HSCT may be reduced by appropriate selection of UDs, with such selection taking into account the functional rules of immunogenetics.
引用
收藏
页码:2984 / 2992
页数:9
相关论文
共 34 条
[11]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[12]   Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: Unadjusted analysis [J].
Klein, JP ;
Rizzo, JD ;
Zhang, MJ ;
Keiding, N .
BONE MARROW TRANSPLANTATION, 2001, 28 (10) :909-915
[13]   Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling [J].
Klein, JP ;
Rizzo, JD ;
Zhang, MJ ;
Keiding, N .
BONE MARROW TRANSPLANTATION, 2001, 28 (11) :1001-1011
[14]   Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age [J].
Kollman, C ;
Howe, CWS ;
Anasetti, C ;
Antin, JH ;
Davies, SM ;
Filipovich, AH ;
Hegland, J ;
Kamani, N ;
Kernan, NA ;
King, R ;
Ratanatharathorn, V ;
Weisdorf, D ;
Confer, DL .
BLOOD, 2001, 98 (07) :2043-2051
[15]   Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes [J].
La Nasa, G ;
Giardini, C ;
Argiolu, F ;
Locatelli, F ;
Arras, M ;
De Stefano, P ;
Ledda, A ;
Pizzati, A ;
Sanna, MA ;
Vacca, A ;
Lucarelli, G ;
Contu, L .
BLOOD, 2002, 99 (12) :4350-4356
[16]   Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease [J].
Locatelli, F ;
Rocha, V ;
Reed, W ;
Bernaudin, F ;
Ertem, M ;
Grafakos, S ;
Brichard, B ;
Li, XX ;
Nagler, A ;
Giorgiani, G ;
Haut, PR ;
Brochstein, JA ;
Nugent, DJ ;
Blatt, J ;
Woodard, P ;
Kurtzberg, J ;
Rubin, CM ;
Miniero, R ;
Lutz, P ;
Raja, T ;
Roberts, I ;
Will, AM ;
Yaniv, I ;
Vermylen, C ;
Tannoia, N ;
Garnier, F ;
Ionescu, I ;
Walters, MC ;
Lubin, BH ;
Gluckman, E .
BLOOD, 2003, 101 (06) :2137-2143
[17]   HUMAN CYTOMEGALOVIRUS (HCMV) INFECTION IN PEDIATRIC-PATIENTS GIVEN ALLOGENEIC BONE-MARROW TRANSPLANTATION - ROLE OF EARLY ANTIVIRAL TREATMENT FOR HCMV ANTIGENEMIA ON PATIENTS OUTCOME [J].
LOCATELLI, F ;
PERCIVALLE, E ;
COMOLI, P ;
MACCARIO, R ;
ZECCA, M ;
GIORGIANI, G ;
DESTEFANO, P ;
GERNA, G .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 88 (01) :64-71
[18]   MARROW TRANSPLANTATION IN PATIENTS WITH THALASSEMIA RESPONSIVE TO IRON CHELATION-THERAPY [J].
LUCARELLI, G ;
GALIMBERTI, M ;
POLCHI, P ;
ANGELUCCI, E ;
BARONCIANI, D ;
GIARDINI, C ;
ANDREANI, M ;
AGOSTINELLI, F ;
ALBERTINI, F ;
CLIFT, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (12) :840-844
[19]   Marrow transplantation for patients with thalassemia: Results in class 3 patients [J].
Lucarelli, G ;
Clift, RA ;
Galimberti, M ;
Polchi, P ;
Angelucci, E ;
Baronciani, D ;
Giardini, C ;
Andreani, M ;
Manna, M ;
Nesci, S ;
Agostinelli, F ;
Rapa, S ;
Ripalti, M ;
Albertini, F .
BLOOD, 1996, 87 (05) :2082-2088
[20]   BONE-MARROW TRANSPLANTATION IN PATIENTS WITH THALASSEMIA [J].
LUCARELLI, G ;
GALIMBERTI, M ;
POLCHI, P ;
ANGELUCCI, E ;
BARONCIANI, D ;
GIARDINI, C ;
POLITI, P ;
DURAZZI, SMT ;
MURETTO, P ;
ALBERTINI, F .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (07) :417-421